Marksans Pharma Rises As UK Regulator Approves New Drugs
The company's subsidiary Relonchem, has received marketing authorisation for Rasagiline and Olmesartan drugs.02-07-2024
02-07-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release intimating receipt of marketing authorization from UKMHRA.02-07-2024
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of issuance of duplicate share certificate issued by the Company as attached01-07-2024
MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
Trading window for the designated persons of Marksans Pharma Limited will remain closed from 1st July, 2024 until 48 hours after announcement of Unaudited Financial Results for the quarter ended 30th June, 2024.30-06-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Kindly find attached transcript of earnings call Q4FY2405-06-2024
Marksans Pharma Results Earnings Call for Q4FY24
Conference Call with Marksans Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.31-05-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Kindly find attached31-05-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Audited financial results for quarter and year ended March 31, 202431-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Marksans Pharma Ltd.
Pharmaceuticals company Marksans Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Operating revenue was Rs 560.0 crore, up by 15.2% YoY driven by by volume gains, new launches, addition of new customers, and increase in our share with existing customers Gross profit was Rs 290.2 crore, up by 19.8% YoY with a Gross margin of 51.8% EBITDA was Rs 109.6 crore, grew by 0.1% with an EBITDA margin of 19.6% EPS was at Rs 1.73 FY24 Financial Highlights: Operating revenue was Rs 2,177.4 crore, up by 17.6% YoY US and North America business grew by 18.5% YoY UK and Europe grew by 22.9% YoY Gross profit was Rs 1,139.3 crore, up by 22.4% YoY with a Gross margin of 52.3%. EBITDA was Rs 458.6 crore, grew by 35.1% with an EBITDA margin of 21.1% EPS grew by 8.0% YoY to Rs 6.92 Mark Saldanha, Managing Director of the Company said “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore. We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.” Result PDF30-05-2024
MARKSANS PHARMA LTD. - 524404 - Statement Of Deviation / Variation For Q4FY24
Kindly find enclosed30-05-2024